...
首页> 外文期刊>Journal of drug delivery science and technology >Epigallocatechin gallate loaded electrospun silk fibroin scaffold with anti-angiogenic properties for corneal tissue engineering
【24h】

Epigallocatechin gallate loaded electrospun silk fibroin scaffold with anti-angiogenic properties for corneal tissue engineering

机译:Epigallocatechin Gallate负载电纺丝丝素骨架与角膜组织工程的抗血管生成性能

获取原文
获取原文并翻译 | 示例

摘要

Avascularity is the first requirement for corneal tissue engineering. The goal of this study was to develop an epigallocatechin gallate (EGCG)-loaded silk fibroin-based scaffold with anti-angiogenesis properties for corneal tissue engineering. Silk nanofibers were prepared by electrospinning, and treated with methanol to enhance water insolubility. Scanning electron microscopy, Fourier transform infrared spectroscopy, X-ray diffraction, tensile testing, differential scanning calorimetry, contact angle testing, and porosimetry were used to characterize the scaffold. The suitability of the scaffold as support for limbal cells was demonstrated by scanning electron microscopy. In situ drug loading of EGCG into the scaffold successfully produced a homogeneous structure of nanofibers and the loaded nanofibers released the drug over 144 h in a controlled-manner. The appropriate dose of the anti-angiogenic compound to be loaded in the electrospun nanofibers was determined by MTT assay and using human umbilical vein endothelial cells (HUVEC). The findings showed a dose-dependent inhibition of cell proliferation with the IC50 values of 43.06 +/- 2.51 mu M and 47.1 +/- 3.46 mu M after 24 and 72 h treatment, respectively. The MTT results also revealed that the prepared fibrous scaffolds containing EGCG promoted the inhibition of HUVEC during in vitro incubation. It is anticipated that the EGCG-loaded scaffold has the potential for use as a delivery system for corneal tissue engineering.
机译:缺血是角膜组织工程的第一个要求。该研究的目标是开发一种具有基于丝素蛋白的支架,具有用于角膜组织工程的抗血管生成特性的ePigallocateChin Callate(EGCG)的基础支架。通过静电纺丝制备丝纳米纤维,并用甲醇处理以增强水不溶性。扫描电子显微镜,傅里叶变换红外光谱,X射线衍射,拉伸试验,差示扫描量热法,接触角测试和孔隙率测定来表征支架。通过扫描电子显微镜证明了作为对Limbal细胞支持的支架的适用性。原位药物加载到支架中成功地制备了纳米纤维的均匀结构,负载纳米纤维以受控方式释放出144小时的药物。通过MTT测定法测定待装载在电纺纳米纤维中的适当剂量的抗血管生成化合物,并使用人脐静脉内皮细胞(HUVEC)测定。结果表明,在24和72h治疗后,IC50值的IC 50值为43.06 +/- 2.51 mu m和47.1 +/-3.46μm的剂量依赖性抑制。 MTT结果还表明,含有EGCG的制备的纤维支架促进了在体外孵育过程中抑制Huvec。预计eGCG装载的脚手架具有用作角膜组织工程的输送系统。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号